GFM
SNDX icon

GF Fund Management’s Syndax Pharmaceuticals SNDX Stock Holding History

GF Fund Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.8K Sell
1,868
-84
-4% -$1.75K ﹤0.01% 411
2026
Q1 		$45.6K Buy
1,952
+244
+14% +$5.3K ﹤0.01% 410
2025
Q4 		$35.9K Sell
1,708
-145
-8% -$2.53K ﹤0.01% 439
2025
Q3 		$28.5K Sell
1,853
-333
-15% -$4.36K ﹤0.01% 448
2025
Q2 		$20.5K Hold
2,186
– – ﹤0.01% 501
2025
Q1 		$26.9K Buy
2,186
+394
+22% +$5.56K ﹤0.01% 471
2024
Q4 		$23.7K Buy
+1,792
New +$30.7K ﹤0.01% 458

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

GF Fund Management's SNDX Position: Q2 2026 in Review

GF Fund Management reduced its Syndax Pharmaceuticals (SNDX) stake by 4.3% in Q2 2026, selling an estimated $1.75K and leaving 1,868 shares worth $40.8K. The position accounts for ﹤0.01% of the portfolio, ranked #411.

GF Fund Management first reported a position in SNDX in Q4 2024 and has held it in 7 quarters since. The position peaked at $45.6K in Q1 2026. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • GF Fund Management held 1,868 shares of Syndax Pharmaceuticals worth $40.8K as of Q2 2026.
  • GF Fund Management sold 84 Syndax Pharmaceuticals shares in Q2 2026, an estimated $1.75K.
  • Syndax Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #411 holding.
  • GF Fund Management first reported a position in Syndax Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Syndax Pharmaceuticals position peaked at $45.6K in Q1 2026.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.